# Muscle Volume Versus Muscle Function on a GLP-1

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/muscle-volume-versus-muscle-function

> Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people, and only one of them is what anybody wants.

## Key points

- Psoas muscle volume −9.3% (P<0.001); chair rise and gait speed both slightly better.
- Muscle fat fraction did not change, so the tissue left behind was not fattier.
- Single-arm, n=51, 24 weeks, 1 mg/week, in people with HIV and fatty liver. No control group.
- A scan showing lost lean mass is not by itself evidence of harm.

The standard worry about GLP-1 drugs is that they take muscle along with fat, and it is a real effect that shows up in every body-composition study. A 2025 analysis measured both halves of the question in the same people and found something the alarming version leaves out: psoas muscle volume fell **9.3%** over 24 weeks, while chair-rise time and walking speed both moved slightly *better*.[1]

## Mass and function are different measurements

This is the distinction the whole debate turns on, and it is usually collapsed. Muscle mass is what a scan measures. Muscle function is whether you can stand up from a chair and walk across a room. They are correlated but not the same, and only one of them is what anybody wants.

In this study, participants received semaglutide for 24 weeks, titrated to 1 mg a week. Psoas muscle volume was measured on MRI and fell by 9.3%, a highly significant change. Physical function was assessed by a ten-time chair rise and a four-meter gait speed test. Chair rise improved by 1.27 seconds and gait speed by 0.05 meters per second. Neither change was statistically significant, but both pointed the opposite way from the scan.[1]

*The same 46 people, the same 24 weeks, measured two ways. Figures from the published analysis.*

| Measure | Change | Significant? |
| --- | --- | --- |
| Psoas muscle volume | −9.3% (95% CI −13.4 to −5.2) | Yes, P<0.001 |
| Psoas muscle fat fraction | −0.42% (95% CI −1.00 to 0.17) | No, P=0.16 |
| Ten-time chair rise | 1.27 seconds faster | No |
| Four-meter gait speed | 0.05 m/s faster | No |

> **The fat-fraction row matters more than it looks.** Muscle fat did not increase, which means the muscle that remained was not becoming proportionally fattier. In other words, the tissue lost was not disproportionately the contractile part. A smaller muscle of unchanged quality is a very different finding from a wasting one. The same pattern appears in the thigh MRI data discussed in [Ozempic butt](https://glpwatchdog.org/research/ozempic-butt-what-changes).

## Why the muscle loss is expected, not alarming on its own

Losing weight of any kind costs lean tissue. It happens with dieting, with bariatric surgery and with illness, and it happens because a smaller body needs less muscle to move itself. Since lean mass always falls, the question that matters is whether the person ends up weaker.

On that question, this study is reassuring and thin. Our article on [what the trials measured](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss) covers the body-composition side in the larger programs, and the practical response, resistance training and adequate protein, has not changed and is not controversial.

## The comparison that answers the question best

A larger MRI study went further, and it did the one thing that turns muscle numbers into an answer: it compared them against what would be *expected anyway*. SURPASS-3’s imaging substudy scanned 246 people with type 2 diabetes at baseline and week 52, randomized to tirzepatide at three doses or to titrated insulin, and then set the results against longitudinal MRI data from UK Biobank participants.[2]

*Pooled tirzepatide, baseline to week 52. Muscle volume Z score is constructed to be invariant to sex, height, weight and BMI.[2]*

| Measure | Change | 95% CI |
| --- | --- | --- |
| Muscle fat infiltration | −0.36 percentage points | −0.48 to −0.25 |
| Muscle volume | −0.64 L | −0.74 to −0.54 |
| Muscle volume Z score | −0.22 | −0.29 to −0.15 |

Read alone, that is the alarming version: muscle volume down, and down relative to what body size would predict. All three changes reached p<0.0001 and all three differed significantly from the insulin arm, where body weight and muscle volume both rose modestly.

> **Now the population comparison, which is the part worth carrying.** The muscle volume that tirzepatide participants lost was *no different from what population data predicted* for people undergoing that change: a mean difference against the population estimate of −0.04 L (95% CI −0.11 to 0.03, p = 0.22). And the reduction in muscle *fat infiltration* was significantly **greater** than predicted (−0.42 percentage points, 95% CI −0.54 to −0.31, p < 0.0001).

So the muscle that went was about what you would expect to go. The muscle that stayed was **less infiltrated with fat than expected**. Fat infiltration is a measure of muscle quality, and it moved in the favorable direction beyond what the weight loss alone would account for.

The insulin arm makes the same point from the other side. Those participants gained weight and gained muscle volume, and their muscle fat infiltration did not significantly improve. They ended up with more muscle of no better quality, which is why volume on its own is not the thing to want.

Two limits apply. This was a post-hoc exploratory analysis in people with type 2 diabetes and fatty liver, not a general population. And a UK Biobank comparison is a modeled expectation rather than a matched control group. It is a good model, but not the same as randomizing people to lose weight another way.

## How much weight this can carry

For the semaglutide study, not much. It was a **single-arm study** with no control group. Everyone received the drug, so a functional improvement cannot be attributed to it. People who enroll in a study, lose weight and get tested twice may walk faster for reasons that have nothing to do with semaglutide.

- **51 participants**, with muscle measures in 46. Small enough that the non-significant functional results may be underpowered rather than flat.
- **24 weeks**, and titrated only to 1 mg a week, below the 2.4 mg used for weight management. Both the duration and the dose are modest.
- **A specific population**: people with HIV and metabolic dysfunction-associated steatotic liver disease, with a mean age of 50 and a mean BMI of 35.5.
- **A secondary analysis.** The parent study, SLIM LIVER, was designed to ask about liver fat. Muscle was not its primary question.

> A single-arm study cannot tell you what a drug did. It can tell you what happened, which is sometimes enough to correct a bad assumption.

That is its value. It does not prove GLP-1 drugs preserve function. It does show that a substantial fall in measured muscle volume can happen alongside stable or slightly improved physical performance. So a scan showing lost lean mass is not, by itself, evidence that someone has been harmed. The ten papers we rely on for the muscle question are in [our muscle reading list](https://glpwatchdog.org/research/lists/top-glp1-muscle-preservation-studies).

## Frequently asked questions

### Do GLP-1 drugs cause muscle loss?

Lean tissue does fall. In this study, psoas muscle volume dropped 9.3% over 24 weeks. That happens with weight loss of any kind, including dieting and surgery, because a smaller body needs less muscle to move itself. Whether it leaves people weaker is a separate question.

### Does losing muscle mass mean losing strength?

Not necessarily, and this study is a clear example. While muscle volume fell 9.3%, ten-time chair rise and four-meter gait speed both moved slightly in the better direction, though neither significantly. Mass is what a scan measures; function is what you use.

### How reliable is this finding?

Limited. It was a single-arm study of 51 people with no control group, over 24 weeks, at a dose below the weight-management one, in people with HIV and fatty liver disease. It cannot show what the drug caused, only what happened alongside it.

### Did the remaining muscle get worse in quality?

It does not appear to have. Muscle fat fraction did not change significantly, meaning the tissue that remained was not becoming proportionally fattier. A smaller muscle of unchanged quality is different from a wasting one.

### What should someone do about muscle loss on a GLP-1?

The answer has not changed and is not controversial: resistance training and adequate protein while losing weight. Nothing in this study alters that, and nothing in it suggests the loss is harmless either. What it suggests is that a scan alone does not tell you whether harm occurred.

## References

1. Ditzenberger GL, Lake JE, Kitch DW, et al. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clinical Infectious Diseases. 2025. PMID: 39046173. https://pubmed.ncbi.nlm.nih.gov/39046173/
2. Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. 2025. PMID: 40318682. https://pubmed.ncbi.nlm.nih.gov/40318682/

---

Cite as: GLP Watchdog, Nora Bissett, "Muscle Volume Versus Muscle Function on a GLP-1", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/muscle-volume-versus-muscle-function

Canonical HTML page: https://glpwatchdog.org/research/muscle-volume-versus-muscle-function

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
